PARIS (Reuters) -French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday.

Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion.